Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, North Shore University Hospital - Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, USA.
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, North Shore University Hospital - Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, USA.
J Perinat Med. 2021 Nov 26;50(3):300-304. doi: 10.1515/jpm-2021-0495. Print 2022 Mar 28.
To determine whether preimplantation genetic testing for aneuploidy (PGT-A) is associated with a reduced risk of abnormal conventional prenatal screening results in singleton pregnancies conceived using fertilization (IVF).
This was a retrospective cohort study of singleton IVF pregnancies conceived from a single tertiary care center between January 2014 and September 2019. Exclusion criteria included mosaic embryo transfers, vanishing twin pregnancies, and cycles with missing outcome data. Two cases of prenatally diagnosed aneuploidy that resulted in early voluntary terminations were also excluded. The primary outcome of abnormal first or second-trimester combined screening results was compared between two groups: pregnancy conceived after transfer of a euploid embryo by PGT-A vs. transfer of an untested embryo. Multivariable backwards-stepwise logistic regression with Firth method was used to adjust for potential confounders.
Of the 419 pregnancies included, 208 (49.6%) were conceived after transfer of a euploid embryo by PGT-A, and 211 (50.4%) were conceived after transfer of an untested embryo. PGT-A was not associated with a lower likelihood of abnormal first-trimester (adjusted OR 1.64, 95% CI 0.82-3.39) or second-trimester screening results (adjusted OR 0.96, 95% CI 0.56-1.64). The incidences of cell-free DNA testing, fetal sonographic abnormalities, genetic counseling, and invasive prenatal diagnostic testing were similar between the two groups.
Our data suggest that PGT-A is not associated with a change in the likelihood of abnormal prenatal screening results or utilization of invasive prenatal diagnostic testing. Counseling this patient population regarding the importance of prenatal screening and prenatal diagnostic testing, where appropriate, remains essential.
确定胚胎植入前遗传学检测(PGT-A)是否与使用体外受精(IVF)受孕的单胎妊娠中异常常规产前筛查结果的风险降低相关。
这是一项回顾性队列研究,纳入了 2014 年 1 月至 2019 年 9 月期间在一家三级保健中心接受 IVF 的单胎妊娠。排除标准包括嵌合体胚胎移植、双胎消失妊娠和缺少结局数据的周期。也排除了 2 例产前诊断为非整倍体导致早期自愿终止妊娠的病例。比较两组异常的 1 期或 2 期联合筛查结果:通过 PGT-A 移植整倍体胚胎受孕与未检测胚胎移植受孕。采用 Firth 方法的多变量向后逐步逻辑回归来调整潜在混杂因素。
在纳入的 419 例妊娠中,208 例(49.6%)是通过 PGT-A 移植整倍体胚胎受孕的,211 例(50.4%)是通过未检测胚胎移植受孕的。PGT-A 与较低的异常 1 期(校正 OR 1.64,95%CI 0.82-3.39)或 2 期筛查结果(校正 OR 0.96,95%CI 0.56-1.64)的可能性无关。两组间游离 DNA 检测、胎儿超声异常、遗传咨询和有创产前诊断检测的发生率相似。
我们的数据表明,PGT-A 与异常产前筛查结果的可能性或有创产前诊断检测的使用无关。对这一患者群体进行产前筛查和产前诊断检测的重要性咨询仍然至关重要,在适当的情况下进行。